Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H24N4O6S2 |
Molecular Weight | 420.504 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O
InChI
InChIKey=AVAACINZEOAHHE-VFZPANTDSA-N
InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1
DescriptionSources: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4364b1-02-johnson.pdfCurator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446428/#B1
Sources: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4364b1-02-johnson.pdf
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446428/#B1
Doripenem is a synthetic carbapenem that has broad antibacterial potency against aerobic and anaerobic gram-positive and gram-negative bacteria. Doripenem is structurally related to beta-lactam antibiotics and shares the bactericidal mode of action of other β-lactam antibiotics by targeting penicillin-binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall. Doripenem is resistant to hydrolysis by most β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem has many similarities to the other carbapenems, as well as some important differences, such as greater potency against Pseudomonas aeruginosa. It was found to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122383/
Curator's Comment: Doripenem penetrates the intact blood-brain barrier to a small but measurable extent.
Originator
Curator's Comment: Shionogi (Japan) is the drug's originator and markets doripenem under the brand name Finibax. Peninsula Pharmaceuticals acquired development and marketing rights to doripenem in the US in a licensing agreement signed with Shionogi in 2003. Doripenem is part of Johnson &' Johnson's anti-infective R&D portfolio following the acquisition of Peninsula Pharmaceuticals in 2005.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
47.6 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | DORIBAX Approved UseIndicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli
including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date2007 |
|||
Curative | DORIBAX Approved UseIndicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli
including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date2007 |
|||
Curative | DORIBAX Approved UseIndicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli
including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.87 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.94 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/ |
250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
23 μg/mL |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
66.4 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010 |
1000 mg 3 times / day multiple, intravenous dose: 1000 mg route of administration: intravenous experiment type: multiple co-administered: |
DORIPENEM serum | Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN |
|
47.1 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010 |
500 mg 3 times / day multiple, intravenous dose: 500 mg route of administration: intravenous experiment type: multiple co-administered: |
DORIPENEM serum | Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN |
|
52.98 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
70.64 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/ |
250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
36.3 μg × h/mL |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.4 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010 |
1000 mg 3 times / day multiple, intravenous dose: 1000 mg route of administration: intravenous experiment type: multiple co-administered: |
DORIPENEM serum | Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN |
|
2.2 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010 |
500 mg 3 times / day multiple, intravenous dose: 500 mg route of administration: intravenous experiment type: multiple co-administered: |
DORIPENEM serum | Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN |
|
2.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/ |
250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1 h |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
91.9% |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DORIPENEM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Disc. AE: Transaminases increased, Allergic reaction... Other AEs: Leukopenia, Diarrhea... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Other AEs:Allergic reaction (1 patient) Leukopenia (1 patient) Sources: Diarrhea (11 patient) Nausea (9 patients) Vomiting (9 patients) Headache (6 patients) Oral candidiasis (3 patients) Rash (2 patients) |
500 mg 3 times / day steady, intravenous Recommended Dose: 500 mg, 3 times / day Route: intravenous Route: steady Dose: 500 mg, 3 times / day Sources: |
unhealthy, 54 years (range: 18-90 years) Health Status: unhealthy Age Group: 54 years (range: 18-90 years) Sex: M+F Sources: |
Disc. AE: Nausea, Vulval mycotic infection... AEs leading to discontinuation/dose reduction: Nausea (0.2%) Sources: Vulval mycotic infection (0.1%) Rash (0.1%) |
5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unknown, <8 weeks |
Other AEs: Anemia neonatal, Hypoalbuminemia... Other AEs: Anemia neonatal (3 patients) Sources: Hypoalbuminemia (3 patients) Hyperglycemia (2 patients) Peripheral edema (1 patient) Patent ductus arteriosus (2 patients) |
8 mg/kg single, intravenous Dose: 8 mg/kg Route: intravenous Route: single Dose: 8 mg/kg Sources: |
unknown, >8 weeks <44 weeks Health Status: unknown Age Group: >8 weeks <44 weeks Sex: M+F Sources: |
Other AEs: Anemia neonatal, Peripheral edema... Other AEs: Anemia neonatal (1 patient) Sources: Peripheral edema (1 patient) Dermatitis diaper (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Leukopenia | 1 patient | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Allergic reaction | 1 patient Disc. AE |
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Transaminases increased | 1 patient Disc. AE |
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Diarrhea | 11 patient | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Rash | 2 patients | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Oral candidiasis | 3 patients | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Headache | 6 patients | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Nausea | 9 patients | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Vomiting | 9 patients | 2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: |
Rash | 0.1% Disc. AE |
500 mg 3 times / day steady, intravenous Recommended Dose: 500 mg, 3 times / day Route: intravenous Route: steady Dose: 500 mg, 3 times / day Sources: |
unhealthy, 54 years (range: 18-90 years) Health Status: unhealthy Age Group: 54 years (range: 18-90 years) Sex: M+F Sources: |
Vulval mycotic infection | 0.1% Disc. AE |
500 mg 3 times / day steady, intravenous Recommended Dose: 500 mg, 3 times / day Route: intravenous Route: steady Dose: 500 mg, 3 times / day Sources: |
unhealthy, 54 years (range: 18-90 years) Health Status: unhealthy Age Group: 54 years (range: 18-90 years) Sex: M+F Sources: |
Nausea | 0.2% Disc. AE |
500 mg 3 times / day steady, intravenous Recommended Dose: 500 mg, 3 times / day Route: intravenous Route: steady Dose: 500 mg, 3 times / day Sources: |
unhealthy, 54 years (range: 18-90 years) Health Status: unhealthy Age Group: 54 years (range: 18-90 years) Sex: M+F Sources: |
Peripheral edema | 1 patient | 5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unknown, <8 weeks |
Hyperglycemia | 2 patients | 5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unknown, <8 weeks |
Patent ductus arteriosus | 2 patients | 5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unknown, <8 weeks |
Anemia neonatal | 3 patients | 5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unknown, <8 weeks |
Hypoalbuminemia | 3 patients | 5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unknown, <8 weeks |
Anemia neonatal | 1 patient | 8 mg/kg single, intravenous Dose: 8 mg/kg Route: intravenous Route: single Dose: 8 mg/kg Sources: |
unknown, >8 weeks <44 weeks Health Status: unknown Age Group: >8 weeks <44 weeks Sex: M+F Sources: |
Peripheral edema | 1 patient | 8 mg/kg single, intravenous Dose: 8 mg/kg Route: intravenous Route: single Dose: 8 mg/kg Sources: |
unknown, >8 weeks <44 weeks Health Status: unknown Age Group: >8 weeks <44 weeks Sex: M+F Sources: |
Dermatitis diaper | 2 patients | 8 mg/kg single, intravenous Dose: 8 mg/kg Route: intravenous Route: single Dose: 8 mg/kg Sources: |
unknown, >8 weeks <44 weeks Health Status: unknown Age Group: >8 weeks <44 weeks Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
unlikely | |||
Page: 15.0 |
unlikely | |||
Page: 15.0 |
unlikely | |||
Page: 15.0 |
unlikely | |||
Page: 15.0 |
unlikely | |||
Page: 15.0 |
unlikely |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 13.0 |
no | |||
Sources: https://doi.org/10.1016/j.ijantimicag.2011.11.019 Page: 2.0 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 10.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Doripenem: S 4661. | 2003 |
|
Gateways to clinical trials. | 2003 Dec |
|
Activities of doripenem (S-4661) against drug-resistant clinical pathogens. | 2004 Aug |
|
Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. | 2004 Dec |
|
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. | 2004 Jul |
|
Antibacterial Drug Discovery and Development Summit - Tenth Annual SRI Summit. | 2005 May |
|
Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. | 2005 Oct |
|
Acquisitions not a cure for anti-infectives. | 2005 Sep |
|
Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem. | 2006 Dec |
|
Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. | 2006 Jan-Feb |
|
Doripenem. | 2006 Jun |
|
Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. | 2006 Sep 1 |
|
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. | 2007 Dec |
|
Biochemical characterisation of the CTX-M-14 beta-lactamase. | 2007 Feb |
|
Carbapenems in the USA: focus on doripenem. | 2007 Oct |
|
Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. | 2008 |
|
Doripenem: a review of its use in the treatment of bacterial infections. | 2008 |
|
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in? | 2008 |
|
[Clinical examination of doripenem for infectious diseases in gynecological and associated fields]. | 2008 Apr |
|
Gateways to clinical trials. December 2008. | 2008 Dec |
|
New developments in carbapenems. | 2008 Dec |
|
What's new and not so new on the antimicrobial horizon? | 2008 Dec |
|
[In-vitro activity of panipenem against clinical isolates in 2006]. | 2008 Feb |
|
Carbapenems: a potent class of antibiotics. | 2008 Jan |
|
Doripenem (Doribax)--a new parenteral carbapenem. | 2008 Jan 28 |
|
New drugs: doripenem, raltegravir, and ixabepilone. | 2008 Jan-Feb |
|
Doripenem (Doribax): the newest addition to the carbapenems. | 2008 Jul |
|
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. | 2008 Mar |
|
Current status of newer antiinfectives. | 2008 Nov |
|
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. | 2008 Nov |
|
Lucasti et al in the May 2008 issue of Clinical Therapeutics. | 2008 Oct |
|
Current treatment of pseudomonal infections in the elderly. | 2009 |
|
Current status of newer carbapenems. | 2009 |
|
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. | 2009 Apr |
|
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. | 2009 Apr |
|
Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. | 2009 Aug |
|
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. | 2009 Feb |
|
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. | 2009 Jan |
|
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. | 2009 Jul |
|
An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible. | 2009 Jul |
|
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. | 2009 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf
Curator's Comment: Administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age. For complicated intra-abdominal infection 5-14 days, for complicated UTI, including pyelonephritis 10 days.
500 mg administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age; for complicated intra-abdominal infection 5–14 days, for complicated UTI, including pyelonephritis 10 days.
Route of Administration:
Intravenous
HardyDisk™ Doripenem Antimicrobial Susceptibility Test Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. The concentration of doripenem 10ug has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Proteus
mirabilis, Pseudomonas aeruginosa, Streptococcus constellatus, Streptococcus intermedius
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000175496
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NCI_THESAURUS |
C260
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
DORIBAX (WITHDRAW: URINARY TRACT INFECTIONS)
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
FDA ORPHAN DRUG |
188104
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
WHO-ATC |
J01DH04
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
NDF-RT |
N0000011294
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
LIVERTOX |
NBK548111
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
||
|
WHO-VATC |
QJ01DH04
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C099245
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
C65470
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
DTXSID2046678
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
BHV525JOBH
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
4149
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
DB06211
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
m4744
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
RR-37
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
SUB22196
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL491571
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
148016-81-3
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
Doripenem
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
119771
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
73303
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
7975
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
100000089808
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY | |||
|
DORIPENEM
Created by
admin on Mon Mar 31 18:17:36 GMT 2025 , Edited by admin on Mon Mar 31 18:17:36 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)